Csenge Advisory Group’s Evogene EVGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-2,076
Closed -$13.5K 721
2024
Q2
$13.5K Sell
2,076
-1,000
-33% -$6.98K ﹤0.01% 657
2024
Q1
$23.1K Hold
3,076
﹤0.01% 700
2023
Q4
$25.8K Hold
3,076
﹤0.01% 653
2023
Q3
$18K Buy
3,076
+20
+0.7% +$175 ﹤0.01% 631
2023
Q2
$32.7K Buy
3,056
+600
+24% +$4.06K ﹤0.01% 647
2023
Q1
$15.5K Sell
2,456
-500
-17% -$3.72K ﹤0.01% 594
2022
Q4
$20.7K Sell
2,956
-240
-8% -$1.69K ﹤0.01% 592
2022
Q3
$27K Hold
3,196
﹤0.01% 604
2022
Q2
$24K Sell
3,196
-450
-12% -$4.4K ﹤0.01% 565
2022
Q1
$47K Buy
3,646
+776
+27% +$10.5K ﹤0.01% 622
2021
Q4
$96K Sell
2,870
-600
-17% -$13.6K 0.01% 539
2021
Q3
$91K Buy
3,470
+600
+21% +$17.5K 0.01% 565
2021
Q2
$96K Buy
2,870
+500
+21% +$19.6K 0.01% 542
2021
Q1
$110K Buy
2,370
+720
+44% +$44.6K 0.01% 485
2020
Q4
$78K Buy
+1,650
New +$58.2K 0.01% 426

Other funds holding EVGN

Csenge Advisory Group's EVGN Position: Q3 2024 in Review

Csenge Advisory Group sold out of Evogene (EVGN) in Q3 2024, closing a stake of 2,076 shares — an estimated $13.5K sold.

Csenge Advisory Group first reported a position in EVGN in Q4 2020 and held it in 15 quarters. The position peaked at $110K in Q1 2021. 14 funds tracked by Wall St. Rank hold EVGN as of Q3 2024.

  • Csenge Advisory Group reported no remaining Evogene position as of Q3 2024 after selling out during the quarter.
  • Csenge Advisory Group sold 2,076 Evogene shares in Q3 2024, an estimated $13.5K.
  • Csenge Advisory Group first reported a position in Evogene in Q4 2020 and held it in 15 quarters.
  • Csenge Advisory Group's Evogene position peaked at $110K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Evogene as of Q3 2024.

Based on Csenge Advisory Group's 13F filing for Q3 2024, filed 13 Nov 2024.